Silvia S.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Evaluation of Atezolizumab Combined with Radiotherapy in Muscle-Invasive Bladder Cancer Patients for Pathological Complete Response
- Phase III Randomized Double-Blind Trial of Tiragolumab and Atezolizumab Versus Placebo and Atezolizumab in Resected Stage IIB-IIIB PD-L1 Positive NSCLC
- Phase II Trial of Chemotherapy and Atezolizumab in Stage IIIA/IIIB NSCLC with Atezolizumab Adjuvant and Maintenance Therapy
Data & Insights
Has run more than one trial at 9 of 128 partner sites.
Specializations
Lung Cancer Research
Specializes in treating non-small cell lung cancer (NSCLC) with particular focus on advanced and unresectable cases. The investigator has extensive experience in managing patients with EGFR mutation-positive variants of the disease.
- Stage III NSCLC Management
- EGFR-Targeted Therapies
- Combination Immunotherapy Approaches
Explores innovative treatment combinations including chemoradiation and targeted biological therapies.
Melanoma Studies
Conducts research in the treatment of resectable stage III and IV melanoma, focusing on novel immunotherapy combinations and perioperative therapeutic approaches.
- Perioperative Treatment Strategies
- Immunotherapy Combinations
- Pathological Response Assessment
Investigates cutting-edge therapeutic combinations to improve patient outcomes in advanced melanoma cases.
Bladder Cancer Expertise
Focuses on treating muscle-invasive bladder cancer through innovative approaches combining immunotherapy with radiation therapy.
- Bladder Preservation Techniques
- Concurrent Radiotherapy
- Immunotherapy Integration
Develops therapeutic strategies aimed at organ preservation while maintaining treatment efficacy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.